ImmunoGen’s Merger with AbbVie Awaits Shareholder Approval

Immunogen (IMGN) has released an update.

ImmunoGen, Inc. entered into a Merger Agreement with AbbVie and its subsidiaries on November 30, 2023, with ImmunoGen set to survive as a subsidiary post-merger. The German Federal Cartel Office approved the merger unconditionally on January 29, 2024. Completion of the merger is subject to further conditions, including approval by ImmunoGen’s shareholders and compliance with the Hart-Scott-Rodino Antitrust Improvements Act. ImmunoGen has filed a definitive proxy statement with the SEC and is soliciting votes from shareholders regarding the merger.

For further insights into IMGN stock, check out TipRanks’ Stock Analysis page.